Avacta confirms lateral flow tests can detect Omicron variant
Avacta confirms lateral flow tests can detect Omicron variant
Read moreThu, 06th Aug 2020 10:39
Avacta confirms lateral flow tests can detect Omicron variant
Read more(Sharecast News) - Aim-listed Avacta said on Wednesday that its AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.
Read moreIN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Monday that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for its chemotherapy drug 'AVA6000'.
Read moreAvacta and Novacyt await UK regulatory approval for Covid-19 tests
Read more(Sharecast News) - Avacta said on Tuesday that it has suspended sales of its AffiDX Covid latest flow rapid antigen tests in the UK while it awaits new approval.
Read moreAvacta hails "transformative" first half despite widening loss
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group reported cash and short-term deposits of £37m at the end of its first half on Thursday, down from £54.5m a year ago and £47.9m at the start of the period.
Read moreAvacta sees pre-clinical development milestone in LG Chem partnership
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Wednesday that a preclinical development milestone has been achieved in its multi-target therapeutics partnership with South Korea's LG Chem Life Sciences, triggering an undisclosed milestone payment.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIN BRIEF: Avacta hires oncology drug developer as therapeutics CSO
Read moreIN BRIEF: Avacta hires cancer doctor Mark Goldberg for board
Read moreAvacta doses first patient in chemotherapy medication trial
Read more(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that the first patient has been dosed in its phase 1 multicentre trial evaluating 'AVA6000', which it described as a "novel pro-drug" of 'doxorubicin', and its first therapeutic product based on the proprietary 'preCISION' technology.
Read more